International STAR Registry on CytoSorb Use for Removing Antithrombotic Agents in Hospital Patients

What this Trial Is About

Researchers are collecting real-world data on how the CytoSorb device is used to remove antithrombotic agents in hospital patients. The registry aims to understand clinical use patterns and related outcomes, particularly focusing on reducing bleeding risks linked to these medications. Both past and current patient data will be included to provide comprehensive insights. The study involves gathering clinical information on patients who receive CytoSorb treatment specifically for antithrombotic removal during acute hospital care. CytoSorb is a sorbent hemoperfusion device used to filter out these agents. The registry includes both retrospective and prospective data collection, with safety monitored by tracking any device-related adverse events. Participants clinical outcomes will be followed for up to 30 days after their procedure. Key measurements include bleeding complications and the need for blood transfusions or other blood products, assessed until postoperative day 3, ICU discharge, or death, whichever occurs first. This observational registry does not involve experimental treatments but records standard care outcomes to better understand the devices use and safety.

Safe and Timely Antithrombotic Removal (STAR) Registry